Specific Antiviral Activity of Pyrimidinedispirotripiperazinium Alone and in Combination with Acyclovir on a Herpes-Simplex-Virus Infection Model

被引：3

作者：

Novoselova, E. A. ^{[1
]}

Ryabova, O. B. ^{[1
]}

Leneva, I. A. ^{[2
]}

Makarov, V. A. ^{[1
]}

机构：

[1] Russian Acad Sci, AN Bach Inst Biochem, Fed Res Ctr Fundamentals Biotechnol, 33-2b Leninskii Prosp, Moscow 119071, Russia

[2] II Mechnikov Res Inst Vaccines & Sera, 5 Malyi Kazennyi Pereul, Moscow 105064, Russia

来源：

PHARMACEUTICAL CHEMISTRY JOURNAL | 2019年 / 53卷 / 09期

关键词：

pyrimidine-dispirotripiperazinium; acyclovir; herpes simplex virus; HSV-1; herpetic encephalitis;

D O I：

10.1007/s11094-019-02079-9

中图分类号：

R914 [药物化学];

学科分类号：

100701 ;

摘要：

Efficacious antiviral analogs of viral nucleoside DNA-polymerase inhibitors are used to treat infections caused by herpes simplex virus (HSV) although their widespread use in clinical practice has caused drug-resistant HSV strains to develop. The drug substance pyrimidine-dispirotripiperazinium or 3,3-(2-methyl-5-nitropyrimidin-4,6-diyl)-bis-3,12-diaza-6,9-diazoniadispiro[5.2.5.2]hexadecane tetrachloride dihydrochloride (PDSTP) was previously synthesized by us and possessed high antiherpetic activity in vitro. The antiherpetic efficacy of the new drug substance was evaluated in vivo using a herpetic encephalitis mouse model and various treatment regimes (i.p. and peroral administration, monotherapy, combination therapy with acyclovir).

引用

页码：781 / 785

页数：5